Alzamend Neuro (NASDAQ:ALZN) Releases Quarterly Earnings Results

Alzamend Neuro (NASDAQ:ALZN) announced its earnings results on Wednesday. The company reported ($0.04) EPS for the quarter, Yahoo Finance reports.

Alzamend Neuro Trading Down 1.2 %

Shares of NASDAQ:ALZN traded down $0.00 on Friday, reaching $0.22. 28,349 shares of the company’s stock were exchanged, compared to its average volume of 195,509. The company has a fifty day moving average of $0.37 and a 200-day moving average of $0.49. Alzamend Neuro has a twelve month low of $0.21 and a twelve month high of $1.50. The company has a market capitalization of $21.36 million, a price-to-earnings ratio of -1.32 and a beta of 0.01.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the business. Renaissance Technologies LLC acquired a new position in shares of Alzamend Neuro during the 4th quarter worth approximately $28,000. Charles Schwab Investment Management Inc. acquired a new position in shares of Alzamend Neuro during the 4th quarter worth approximately $30,000. HRT Financial LP acquired a new position in shares of Alzamend Neuro during the 4th quarter worth approximately $32,000. Virtu Financial LLC acquired a new position in shares of Alzamend Neuro during the 4th quarter worth approximately $35,000. Finally, Bank of America Corp DE acquired a new position in shares of Alzamend Neuro during the 1st quarter worth approximately $35,000. Institutional investors and hedge funds own 6.37% of the company’s stock.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.